Janux Therapeutics, Inc. (JANX)

Market Cap	993.04M
Revenue (ttm)	10.00M
Net Income (ttm)	-101.90M
Shares Out	60.15M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,141,716
Open	16.40
Previous Close	16.40
Day's Range	16.00 - 16.54
52-Week Range	15.51 - 71.71
Beta	2.81
Analysts	Strong Buy
Price Target	62.00 (+275.53%)
Earnings Date	Nov 6, 2025

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2021
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: JANX
• Website: https://www.januxrx.com

Financial Performance

In 2024, Janux Therapeutics's revenue was $10.59 million, an increase of 30.99% compared to the previous year's $8.08 million. Losses were -$68.99 million, 18.4% more than in 2023.

Analyst Forecast

According to 12 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price target is $62.0, which is an increase of 275.53% from the latest price.

Price Target

$62.0

(275.53% upside)

Analyst Consensus: Strong Buy